
HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. (NASDAQ:RARE) on Monday, representing an attractive opportunity at current levels.
Analyst Raghuram Selvaraju notes that Ultragenyx stock is down 35% year to date, compared to a 2.7% decline in the benchmark XBI index.